Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam
- PMID: 9333044
- PMCID: PMC164089
- DOI: 10.1128/AAC.41.10.2177
Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam
Abstract
Resistance to piperacillin in several isolates of Citrobacter freundii and Enterobacter cloacae was investigated and confirmed to occur at a frequency of 10(-7) to 10(-6). Development of resistance to piperacillin was significantly suppressed by tazobactam but not by clavulanic acid. To elucidate the mechanism by which resistance suppression occurs, the effect of piperacillin plus tazobactam on the induction of AmpC beta-lactamase was analyzed by monitoring the beta-galactosidase activity of an inducible ampC-lacZ gene fusion in Escherichia coli. The combination exerted no inhibitory effect on AmpC beta-lactamase induction. Tazobactam also had no effect on the accumulation of a key intermediate in the AmpC beta-lactamase induction pathway, 1,6-anhydromurotripeptide, in an ampD mutant strain of E. coli. However, the addition of tazobactam to liquid cultures of E. cloacae 40001 in the presence of piperacillin at four times the MIC caused a delay in the recovery of the culture to piperacillin-induced stress. At 16 times the MIC, a complete suppression of regrowth occurred. Analysis of culture viability on piperacillin plates showed that the culture recovery was due to growth by moderately resistant mutants preexisting in the cell population, which at 16 times the MIC became susceptible to the combination. Evidence from the kinetics of inhibition of the E. cloacae 40001 AmpC beta-lactamase by clavulanic acid, sulbactam, and tazobactam and from the effects of these drugs on the frequency of resistance to piperacillin suggests that the suppressive effect of tazobactam on the appearance of resistance is primarily mediated by the beta-lactamase inhibitory activity.
Similar articles
-
Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants).J Antibiot (Tokyo). 1995 Sep;48(9):1027-33. doi: 10.7164/antibiotics.48.1027. J Antibiot (Tokyo). 1995. PMID: 7592048
-
Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.J Antimicrob Chemother. 1990 Feb;25(2):199-208. doi: 10.1093/jac/25.2.199. J Antimicrob Chemother. 1990. PMID: 2158496
-
A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.FEMS Immunol Med Microbiol. 1995 Apr;11(2):107-11. doi: 10.1111/j.1574-695X.1995.tb00096.x. FEMS Immunol Med Microbiol. 1995. PMID: 7640670
-
Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Pharmacotherapy. 2000 Sep;20(9 Pt 2):213S-218S; discussion 224S-228S. doi: 10.1592/phco.20.14.213s.35045. Pharmacotherapy. 2000. PMID: 11001328 Review.
-
Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.J Antimicrob Chemother. 1993 Jan;31 Suppl A:29-38. doi: 10.1093/jac/31.suppl_a.29. J Antimicrob Chemother. 1993. PMID: 8383654 Review.
Cited by
-
Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture.J Am Chem Soc. 2005 Apr 6;127(13):4632-9. doi: 10.1021/ja042984o. J Am Chem Soc. 2005. PMID: 15796528 Free PMC article.
-
Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone.Antimicrob Agents Chemother. 2021 Jan 20;65(2):e01038-20. doi: 10.1128/AAC.01038-20. Print 2021 Jan 20. Antimicrob Agents Chemother. 2021. PMID: 33139285 Free PMC article.
-
Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae.PLoS One. 2019 Jul 8;14(7):e0218589. doi: 10.1371/journal.pone.0218589. eCollection 2019. PLoS One. 2019. PMID: 31283769 Free PMC article.
-
Clinical role of beta-lactam/beta-lactamase inhibitor combinations.Drugs. 2003;63(14):1511-24. doi: 10.2165/00003495-200363140-00006. Drugs. 2003. PMID: 12834367 Review.
-
Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.Support Care Cancer. 2003 Jun;11(6):362-70. doi: 10.1007/s00520-003-0463-7. Epub 2003 Apr 11. Support Care Cancer. 2003. PMID: 12690546 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases